A Study of HB0030 Injection in Patients With Advanced Solid Tumors

Summary

This is a phase Ia single-center, open-label, dose escalation study.The objectives of this study are to evaluate the safety, toxicity, tolerability, pharmacokinetics/pharmacodynamics(PK/PD), immunogenicity, biomarkers, and antitumor activity of HB0030 in advanced solid tumor subjects.

Conditions

• Advanced Solid Tumor

Interventions

DRUG

HB0030 injection

0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Sponsors & Collaborators

• The First Affiliated Hospital of Bengbu Medical University

  collaborator OTHER

• Huabo Biopharm Co., Ltd.

  lead INDUSTRY

Principal Investigators

• huan zhou, master · The First Affiliated Hospital of Bengbu Medical University

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-12-21

Primary Completion

2023-09-30

Completion

2023-09-30

Countries

• China

Study Locations